We have to base our estimates off what the PMPRB's estimates are. The savings to employers would be somewhere around 10% of what's spent currently, which is a significant amount of money. It would be in the billions of dollars, over time, that we would expect to be passed through to employers, and that would, like I said in my notes, allow the capacity and the room for them to contemplate providing funding for these new medications. The envelope is getting full, and the idea that there's even the capacity to pay for some of these new medications, if we don't make some room on what we're already covering, I don't think is correct. We need to address the prices in order for us to be able to even contemplate some of these new therapies.
On December 11th, 2020. See this statement in context.